Good Clinical Practice Quiz 1 Prep

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/46

encourage image

There's no tags or description

Looks like no tags are added yet.

47 Terms

1
New cards

Definition of Impartial Witness

A person who is independent of the trial who cannot be unfairly influenced by people involved with the trial, who attends the informed consent process if the participant or the participant’s legally acceptable representative cannot read, and who reads the informed consent form and any other documented information supplied or read to the participant and/or their legally acceptable representative.

2
New cards

Definition of Ethics Committee (EC)

An independent body (a review board or a committee, institutional, regional, national, or supranational), constituted of medical / scientific professionals and non-medical / non-scientific members, whose responsibility is to ensure the protection of the rights, safety and well-being of human participants involved in a trial and to provide public assurance of that protection, by, among other things, reviewing and approving / providing favourable opinion on the trial protocol, the suitability of the investigator(s), facilities, and the methods and material to be used in obtaining and documenting informed consent of the trial participants.

3
New cards

Definition of Informed consent

A process by which a participant or their legally acceptable representative voluntarily confirms their willingness to participate in a trial after having been informed and been provided with the opportunity to discuss all aspects of the trial that are relevant to the participant’s decision to participate. Varied approaches to the provision of information and the discussion about the trial can be used. This may include, for example, providing text in different formats, images and videos and using telephone or video conferencing with investigator site staff. Informed consent is documented by means of a written (paper or electronic), signed and dated informed consent form. Obtaining consent remotely may be considered when appropriate.

4
New cards

Definition of Inspection

The act by a regulatory authority(ies) of conducting an official review of documents, facilities, records and any other resources that are deemed by the authority(ies) to be related to the clinical trial and that may be accessed at the investigator site, at the sponsor’s and/or service provider’s (including CRO’s) facilities, or at other establishments deemed appropriate by the regulatory authority(ies). Some aspects of the inspection may be conducted remotely.

5
New cards

Definition of Institution

Any public or private entity or agency or medical or dental facility where clinical trials are conducted

6
New cards

Definition of Interim Clinical Trial/Study Report

A report of intermediate results and their evaluation based on analyses performed during the course of a trial.

7
New cards

Definition of Investigational Product

A pharmaceutical form of an active ingredient or placebo being tested or used as a reference in a clinical trial, including a product with a marketing authorisation when used or assembled (formulated or packaged) in a way different from the approved form, or when used for an unapproved indication, or when used to gain further information about an approved use. Investigational products should be considered synonymous with drugs, medicines, medicinal products, vaccines and biological products.

8
New cards

Definition of Investigator’s Brochure

A compilation of the clinical and non-clinical data on the investigational product(s) which is relevant to the study of the investigational product(s) in human participants

9
New cards

Definition of Legally Acceptable Representatives

An individual or juridical or other body authorised under applicable law to consent, on behalf of a prospective participant, to the participant’s participation in the clinical trial. When a legally acceptable representative provides consent on behalf of a prospective participant, activities related to the consenting process (and re-consent, if applicable) and, where relevant, activities associated with the withdrawal of consent.

10
New cards

Definition of Monitoring

The act of overseeing the progress of a clinical trial, and of ensuring that it is conducted, recorded, and reported in accordance with the protocol, Standard Operating Procedures (SOPs), Good Clinical Practice (GCP), and the applicable regulatory requirement(s)

11
New cards

Definition of Monitoring Report

A documented report following site and/or centralised monitoring activities.

12
New cards

Definition of Multicentre Trial

A clinical trial conducted according to a single protocol
but at more than one investigator site.

13
New cards

Definition of Quality Assurance (QA)

All those planned and systematic actions that are established to ensure that the trial is performed and the data are generated, documented (recorded) and reported in compliance with GCP and the applicable regulatory requirement(s).

14
New cards

Definition of Quality Control (QC)

The operational techniques and activities undertaken to verify that the requirements for quality of the trial-related activities have been fulfilled.

15
New cards

Definition of SAE

Any untoward medical occurrence that at any dose:

  • results in death

  • is life-threatening

  • requires inpatient hospitalisation or prolongation of existing hospitalisation

  • results in persistent or significant disability/incapacity, or

  • is a congenital anomaly / birth defect


16
New cards

Definition of Source Data

All information in original records and certified copies of original records of clinical findings, observations, or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial.

17
New cards

Definition of Source records

Original documents or data (which includes relevant metadata) or certified copies of the original documents or data, irrespective of the media used. This may include trial participants’ medical/health records/notes/charts; data provided/entered by trial participants (e.g., electronic patient-reported outcomes (ePROs)); healthcare professionals’ records from pharmacies, laboratories and other facilities involved in the clinical trial; and data from automated instruments, such as wearables and sensors.

18
New cards

Definition of Vulnerable Participants

Individuals whose willingness to volunteer in a clinical trial may be unduly influenced by the expectation, whether justified or not, of benefits associated with participation or of a retaliatory response from senior members of a hierarchy in case of refusal to participate. Examples are members of a group with a hierarchical structure, such as medical, pharmacy, dental and nursing students; subordinate hospital and laboratory personnel; employees of the pharmaceutical industry; members of the armed forces; and persons kept in detention. Other vulnerable participants may include persons in nursing homes, unemployed or impoverished persons, patients in emergency situations, ethnic minority groups, homeless persons, nomads, refugees, minors and those incapable of giving consent.

19
New cards

Definition of Well-being (of trial participants)

The physical and mental integrity of the participants participating in a clinical trial.

20
New cards

Definition of Adverse Drug Reaction (ADR)

In the pre-approval clinical experience with a new investigational product or its new usages (particularly as the therapeutic dose(s) may not be established): unfavourable and unintended responses, such as a sign (e.g., laboratory results), symptom or disease related to any dose of a medicinal product where a causal relationship between a medicinal product and an adverse event is a reasonable possibility. The level of certainty about the relatedness of the adverse drug reaction to an investigational product will vary. If the ADR is suspected to be medicinal product-related with a high level of certainty, it should be included in the reference safety information (RSI) and/or the Investigator’s Brochure (IB).

For marketed medicinal products: a response to a drug that is noxious and unintended and that occurs at doses normally used in humans for prophylaxis, diagnosis or therapy of diseases or for modification of physiological function.

21
New cards

Definition of Adverse Event

Any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

22
New cards

Definition of Applicable Regulatory Requirement(S)

Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products.

23
New cards

Definition of Audit

A systematic and independent examination of trial-
related activities and records performed by the sponsor,
service provider (including contract research
organisation (CRO)) or institution to determine whether
the evaluated trial-related activities were conducted and
the data were recorded, analysed and accurately
reported according to the protocol, applicable standard
operating procedures (SOPs), Good Clinical Practice
(GCP) and the applicable regulatory requirement(s).

24
New cards

Definition of Audit Certificate

A declaration of confirmation by the auditor that an audit has taken place.

25
New cards

Definition of Audit Report

A record describing the conduct and outcome of the audit.

26
New cards

Definition of Audit Trail

Metadata records that allow the appropriate evaluation of the course of events by capturing details on actions (manual or automated) performed relating to information and data collection and, where applicable,to activities in computerised systems. The audit trail should show activities, initial entry and changes to data fields or records, by whom, when and, where applicable, why. In computerised systems, the audit trail should be secure, computer-generated and time stamped.

27
New cards

Definition of Case Report Form

A data acquisition tool designed to record protocol-required information to be reported by the investigator to the sponsor on each trial participant

28
New cards

Definition of Clinical Trial/Study

Any investigation in human participants intended to discover or verify the clinical, pharmacological and/or other pharmacodynamic effects of an investigational product(s), and/or to identify any adverse reactions to an investigational product(s), and/or to study absorption, distribution, metabolism, and excretion of an investigational product(s) with the object of ascertaining its safety and/or efficacy. The terms clinical trial and clinical study are synonymous.

29
New cards

Definition of Certified Copy

A copy (irrespective of the type of media used) of the original record that has been verified (i.e., by a dated signature or by generation through a validated process) to have the same information as the original, including relevant metadata, where applicable

30
New cards

Definition of Clinical Trial/Study Report

A documented description of a trial of any investigational product conducted in human participants, in which the clinical and statistical description, presentations and analyses are fully integrated into a single report.

31
New cards

Definition of Compliance (in relation to trials)

Adherence to all the trial-related requirements, Good Clinical Practice (GCP) requirements, and the applicable regulatory requirements.

32
New cards

Definition of Confidentiality

Prevention of disclosure to other than authorised individuals of a sponsor’s proprietary information or of a participant’s identity or their confidential information

33
New cards

Definition of Computerised Systems Validation

A process of establishing and documenting that the specified requirements of a computerised system can be consistently fulfilled from design until decommissioning of the system or transition to a new system. The approach to validation should be based on a risk assessment that takes into consideration the intended use of the system and the potential of the system to affect trial participant protection and the reliability of trial results.

34
New cards

Definition of Co-ordinating Investigator

An investigator assigned the responsibility for the co-ordination of investigators at different centres participating in a multicentre trial.

35
New cards

Definition of Direct Access

Permission to examine, analyse, verify, and reproduce any records and reports that are important to evaluation of a clinical trial. Any party (e.g. domestic and foreign regulatory authorities, sponsor’s monitors and auditors) with direct access should take all reasonable precautions within the constraints of the applicable regulatory requirement(s) to maintain the confidentiality of participants’ identities and sponsor’s proprietary information.

36
New cards

Definition of Data Acquisition Tool (DAT)

A paper or electronic tool designed to collect data and associated metadata from a data originator in a clinical trial according to the protocol and to report the data to the sponsor.

The data originator may be a human (e.g., the participant or trial staff), a machine (e.g., wearables and sensors) or a computer system from which the electronic transfer of data from one system to another has been undertaken (e.g., extraction of data from an electronic health record or laboratory system).

Examples of DATs include but are not limited to CRFs, interactive response technologies (IRTs), clinical outcome assessments (COAs), including patient- reported outcomes (PROs) and wearable devices, irrespective of the media used.

37
New cards

Definition of Essential Records

Essential records are the documents and data (and relevant metadata), in any format, associated with a clinical trial that facilitate the ongoing management of the trial and collectively allow the evaluation of the methods used, the factors affecting a trial and the actions taken during the trial conduct to determine the reliability of the trial results produced and the verification that the trial was conducted in accordance with GCP and applicable regulatory requirements

38
New cards

Definition of Independent Data-Monitoring Committee

An independent data-monitoring committee that may be established by the sponsor to assess at intervals the progress of a clinical trial, the safety data, and the critical efficacy endpoints, and to recommend to the sponsor whether to continue, modify, or stop a trial.

39
New cards

Definition of Meta Data

The contextual information required to understand a given data element. Metadata is structured information that describes, explains or otherwise makes it easier to retrieve, use or manage data. For the purpose of this guideline, relevant metadata are those needed to allow the appropriate evaluation of the trial conduct.

40
New cards

What should Investigators be qualified by?

  • Education

  • Training

  • Experience

  • Assume responsibility for the proper conduct
    of the trial

  • Should provide evidence through up-to-date
    curriculum vitae (CV)


41
New cards

What should the investigator be aware of and comply with?

  • GCP

  • Applicable regulatory requirement


42
New cards

What do investigator’s need to be thoroughly familiar with the appropriate use of the investigational product(s)

  • In the protocol,

  • In the current Investigator Brochure (IB),

  • In the product information,

  • In other information sources provided by the sponsor


43
New cards

What approval is needed before initiating a trial?

Written and dated approval from RA and EC

for

  • The trial protocol

  • Written informed consent form

  • Consent form updates

  • trial participant recruitment procedures (e.g. advertisement)

  • Any other written information to be provided to the trial participants.


44
New cards

Investigator should provide EC with a (Investigator’s Brochure)

  • current copy of the IB

  • product information brochure (PIB)

  • If the IB /PIB is updated during the trial, the
    investigator should supply a copy of the
    updated IB to the EC and RA.


45
New cards

During the trial, the RA and EC should provide

  • any updates to the participant information

  • i.e: revised informed consent document

  • summaries of the trial status

  • any changes significantly affecting the conduct of the trial and/or

  • increase risk to participants


46
New cards

Investigator’s responsibilities during the randomisation and unblinding procedures.

  • Follow the trial’s randomisation procedures

  • Ensure treatment randomisation code is broken only in accordance with the protocol


47
New cards